Utah Medical Products, Inc. UTMD R2K
Company Overview
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Why Investors Should Care
Trades at a P/E of 20.2, below the sector median of 25.4.
Maintains a net profit margin of 28.9%.
Carries low leverage with a debt-to-equity ratio of 0.17.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $38.52M (-5.8% YoY).
- Trailing 12 Months Year-on-year growth — revenue -10.2%, earnings -11.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.51% |
| 1 Year: | -10.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -11.00% |
Stock Price Performance
| 1 Year: | +22.79% |
| 6 Months: | +15.02% |
| 3 Months: | +2.11% |
| 1 Month: | -1.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.46 · Neutral
P/E of 20.19 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 28.9%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UTMD Utah Medical Products, Inc. R2K | 68.25 | 20.19 | $217.31M | 1.80% | 9.51% | 9.14% | 2.51% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 10.26M | 10.83M | 10.12M | 10.20M | 10.89M | 10.96M | 10.39M | 9.76M | 10.73M | 11.85M | 12.49M | 11.83M | 10.90M | 8.79M | 10.48M | 12.01M | 10.96M | 12.60M | 12.57M | 12.91M | 12.32M | 13.43M | 12.96M | 13.57M | 12.52M | 12.87M | 12.51M | 12.33M | 11.34M | 10.40M | 10.01M | 9.16M | 9.71M | 9.95M | 9.81M | 9.04M | 8.72M |
| Gross Profit | 6.22M | 6.25M | 5.78M | 6.54M | 6.89M | 6.50M | 6.47M | 6.92M | 6.98M | 6.29M | 6.11M | 6.77M | 7.50M | 7.38M | 7.81M | 6.84M | 4.95M | 6.50M | 7.26M | 6.95M | 7.79M | 8.07M | 8.11M | 7.53M | 8.15M | 8.19M | 8.33M | 7.84M | 7.74M | 7.36M | 7.10M | 6.77M | 6.25M | 5.80M | 5.32M | 5.54M | 5.59M | 5.60M | 5.26M | 5.28M |
| Operating Income | 4.31M | 4.32M | 3.94M | 4.72M | 5.03M | 4.68M | - | 4.97M | 5.06M | 4.40M | - | 4.10M | 4.48M | 4.37M | - | 3.86M | 1.98M | 3.59M | - | 3.89M | 4.76M | 5.10M | - | 4.52M | 5.06M | 5.14M | - | 4.44M | 4.42M | 3.97M | - | 3.88M | 3.44M | 3.34M | - | 3.15M | 3.20M | 2.61M | - | 2.56M |
| Diluted EPS | 0.85 | 0.86 | 0.78 | 0.95 | 1.04 | 0.97 | -0.67 | 1.09 | 1.15 | 1.80 | 0.91 | 0.84 | 0.94 | 0.99 | 1.17 | 0.84 | 0.36 | 0.80 | 0.94 | 0.83 | 0.94 | 1.15 | 1.13 | 0.96 | 1.12 | 1.18 | 1.25 | 1.16 | 1.15 | 1.08 | 1.18 | 1.09 | 0.98 | 1.03 | 0.86 | 0.92 | 0.94 | 0.82 | 0.80 | 0.82 |
| R&D Expense | 110.00K | 119.00K | 135.00K | 118.00K | 119.00K | 103.00K | - | 113.00K | 117.00K | 108.00K | - | 115.00K | 113.00K | 130.00K | - | 135.00K | 116.00K | 125.00K | - | 130.00K | 128.00K | 127.00K | - | 123.00K | 135.00K | 112.00K | - | 144.00K | 133.00K | 138.00K | - | 266.00K | 255.00K | 172.00K | - | 154.00K | 135.00K | 167.00K | - | 154.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.92M | 25.12M | 37.86M | 41.55M | 40.49M | 41.28M | 40.16M | 39.30M | 41.41M | 42.00M | 46.90M | 42.18M | 49.05M | 52.28M | 50.22M | 40.90M | 38.52M |
| Gross Profit | 13.79M | 13.21M | 22.40M | 25.31M | 24.27M | 24.98M | 24.18M | 23.69M | 26.39M | 26.31M | 29.47M | 25.55M | 30.92M | 32.20M | 30.04M | 24.14M | 22.00M |
| Operating Income | 9.43M | 8.92M | 11.84M | 15.20M | 14.83M | 16.20M | 15.65M | 16.19M | 19.01M | 18.70M | 17.63M | 13.71M | 18.88M | 19.79M | 16.78M | 13.59M | 11.40M |
| Diluted EPS | 1.72 | 1.65 | 2.03 | 2.74 | 3.02 | 3.02 | 3.14 | 3.22 | 2.28 | 4.95 | 3.94 | 2.94 | 4.04 | 4.52 | 4.57 | 3.96 | 3.48 |
| R&D Expense | 361.00K | 397.00K | -518.00K | 563.00K | 491.00K | 460.00K | 522.00K | 475.00K | 447.00K | 454.00K | 483.00K | 486.00K | 526.00K | 493.00K | 560.00K | 813.00K | 668.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 41.24M | 76.39M | 76.94M | 80.71M | 81.08M | 79.17M | 76.19M | 92.75M | 99.77M | 109.79M | 111.75M | 115.64M | 123.87M | 135.46M | 122.54M | 122.54M |
| Total Equity | - | - | 37.79M | 40.76M | 50.97M | 60.58M | 64.56M | 69.65M | 69.24M | 78.12M | 88.99M | 101.09M | 102.82M | 107.14M | 114.25M | 128.31M | 117.43M | 119.27M |
| Cash & Equivalents | 97.00K | 410.00K | 3.82M | 6.53M | 8.87M | 14.39M | 19.27M | 23.28M | 26.30M | 39.88M | 51.11M | 42.79M | 51.59M | 60.97M | 75.05M | 92.87M | 82.98M | 85.76M |
| Long Term Debt | - | - | - | - | - | 9.00K | 5.07K | 1.01K | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | - | - | 3.45M | 35.63M | 25.96M | 20.13M | 16.52M | 9.53M | 6.95M | 14.62M | 10.78M | 8.69M | 8.92M | 8.50M | 9.62M | 7.14M | 5.11M | 3.27M |
| Current Liabilities | - | - | 1.90M | 9.63M | 7.82M | 7.61M | 8.97M | 4.07M | 3.02M | 5.28M | 5.26M | 3.45M | 3.79M | 3.75M | 5.96M | 4.71M | 3.76M | 2.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.23M | 7.16M | 11.37M | 13.56M | 12.31M | 15.39M | 13.80M | 14.53M | 16.91M | 16.83M | 17.06M | 20.14M | 21.20M | 21.15M | 22.28M | 14.83M | 14.69M |
| Investing Cash Flow | -3.16M | 2.71M | -26.68M | -208.00K | -344.00K | -1.13M | -246.00K | -3.30M | -1.60M | 534.00K | -21.54M | -860.00K | -552.00K | -818.00K | -639.00K | -208.00K | -371.00K |
| Financing Cash Flow | -3.77M | -6.42M | 18.08M | -11.17M | -6.60M | -8.26M | -8.89M | -6.34M | -2.65M | -4.78M | -4.23M | -10.73M | -10.90M | -5.48M | -4.17M | -23.84M | -12.34M |
| Capital Expenditure | -466.00K | -1.53M | -247.00K | -254.00K | -339.00K | -1.11M | -176.00K | -3.29M | -1.60M | -402.00K | -540.00K | -860.00K | -552.00K | -809.00K | -639.00K | -230.00K | -371.00K |
| Free Cash Flow | 6.76M | 5.62M | 11.12M | 13.31M | 11.97M | 14.28M | 13.62M | 11.23M | 15.31M | 16.43M | 16.52M | 19.28M | 20.65M | 20.34M | 21.64M | 14.60M | 14.32M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 1.21M | 398.00K | 6.98M | 0 | 2.50M | 0 | 19.97M | 8.36M |
| Dividends Paid | 3.34M | 6.03M | 3.43M | 3.56M | 3.67M | 3.77M | 3.85M | 3.92M | 2.96M | 4.03M | 4.11M | 4.12M | 11.46M | 3.16M | 4.28M | 4.26M | 3.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 53.2% | 52.6% | 59.2% | 60.9% | 59.9% | 60.5% | 60.2% | 60.3% | 63.7% | 62.6% | 62.8% | 60.6% | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% |
| Operating Margin % | 36.4% | 35.5% | 31.3% | 36.6% | 36.6% | 39.3% | 39.0% | 41.2% | 45.9% | 44.5% | 37.6% | 32.5% | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROCE % | - | 22.7% | 17.7% | 22.0% | 20.3% | 22.5% | 20.8% | 22.1% | 21.7% | 19.8% | 16.6% | 12.7% | 16.9% | 16.8% | 12.8% | 11.4% | 9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Brandes Investment Partners L.P. | 14.11% | 449.28K | $32.18M |
| 2 | Dimensional Fund Advisors LP | 6.22% | 197.91K | $14.18M |
| 3 | Blackrock Inc. | 5.89% | 187.65K | $13.44M |
| 4 | Renaissance Technologies, LLC | 5.78% | 184.11K | $13.19M |
| 5 | Vanguard Capital Management LLC | 4.35% | 138.56K | $9.93M |
| 6 | Geode Capital Management, LLC | 3.77% | 120.10K | $8.60M |
| 7 | Minerva Advisors LLC | 2.94% | 93.61K | $6.71M |
| 8 | Hotchkis & Wiley Capital Management, LLC | 2.80% | 89.13K | $6.38M |
| 9 | Rice, Hall, James & Associates LLC | 2.13% | 67.88K | $4.86M |
| 10 | State Street Corporation | 2.02% | 64.40K | $4.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UTMD
(UTMD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPMVhmRHRpWmd6VGJ0dGlXS3Q1V3J6eC1YVnREMGFPbkp3N2NJNUZ2YThpUTZwdm0zUDZHUXRjOEJDbEhMeEs2V3U4U3dQU2U4cEZZUnU0bUxqNTdiS05vVlVzUzIxb2RReDk4dXQyaENjV3luTlNtWnVTdmZ3eDBwQ2ZtTV83c2U2UEV0R0…
UTAH MEDICAL PRODUCTS (UTMD) director reports 150-share bona fide stock gift - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQRXpyRkxVcG9VOUh2NmVBa0VORVpTZHA1WUlOUnRtcks2YmF4SGJoLXBkNmRaQWRHdzBydE41ZWxXWFZWUmhzeTNvc08tT3ZQY1h2VWZYSDlra0FhaUlEOWx0RnVoTVNVcEZUQ2FUSmtEQ1dnQWI0cFd2bVc1SzJIMWo5Z1dkTTRuQmt4Zm…
Enterprise value to EBITDA forward of Utah Medical Products, Inc. – NASDAQ:UTMD - TradingView
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPNTFjQVg4MDhzSXVpUmxqY3d1OTVJUnkyXzJiVTY0bGpYcnFSZ3pBeHhMY0h5aEljaVJIMm9DaXFpa1A2ellwWm5pMWVUYUZNLUhPZG1nRjJLVk9fVE5feTlmcTZ0SzBnUWhjSGdycTRia1NDLTRsbkdQNGZpYzRBXzBua1RaY2ZDaFU5SF…
Utah Medical Gains 32% in a Year: Should You Buy the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNbDJOdFFpSnc2TGFmMXJ5X01xbm1vZWZDbm9NU1lFZ0lmQy00SFNUdENPQ0FPbGp6SVB1SW5fYTRseWZEeVd5cWFtSVR5aERtWjQxZVJ4UjRTLW5SWEhqZEtmUnNmY28yNzhrZHpmNXctQTVoaTRfcTJKek9rcWJjbjdPdkRqWmNESk1JM3…
Utah Medical Products: I Can't Upgrade Shares Until Sales Stabilize (UTMD) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOc0JHcUlXV0t2Y01HallLUUtDOVRQM3hoTXo2NjgyTXJTbDFzOElaRVpPWW4wcnBjNTBnUHJEeVo0dFFOSGNtRlFWU1dIaVdLcVZldFBFbnBRVWZOaHJhQk9PY28xdk84ZkoyT1dlMUU5ZUtBdFVoVjRhRTA3Rm9EUFRVamRkSE9iUGdxWD…
The Zacks Analyst Blog American Express, Intuitive Surgical, Shopify and Utah Medical Products - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOWlAza0M1SDZob1JJNkNpUTlKZXBwTVYxN3ZUNEdnTzR2cG1OdjBXc3RCXzZWM1FVQm43ZlV0RzVNNlFuS3dFLTFRTzVBUW5IU2hwM3NXY0c0UUc5azJqMkFQZU55NV9KdGdFOHV3c2tuVWJ5MzlTbWotSm5ZcTlsNjg2X2FkYzZUYmtaOX…
UTMD — Frequently Asked Questions
What is the current share price of Utah Medical Products, Inc. (UTMD)?
As of 2026-07-14 21:23 PDT, Utah Medical Products, Inc. (UTMD) trades at $68.25 on NasdaqGS. Its 52-week range is $53.01 to $73.97.
What is the market capitalisation of UTMD?
Utah Medical Products, Inc. (UTMD) has a market capitalisation of $217.31M on NasdaqGS.
What is the P/E ratio of UTMD?
UTMD trades at a trailing price-to-earnings (P/E) ratio of 20.19. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.81.
Does UTMD pay a dividend?
Utah Medical Products, Inc. (UTMD) currently offers a dividend yield of 1.80%.
What is the return on equity (ROE) of UTMD?
UTMD has a return on equity (ROE) of 9.14%. Its return on capital employed (ROCE) is 9.51%.
Is UTMD a good stock to buy?
This page provides a data-driven analysis of Utah Medical Products, Inc. (UTMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.